StocksMedium•5 October 2026•
1 min read
AbbVie and Genmab Report Positive Phase 3 Results for Lymphoma Treatment
Key Facts
1A Phase 3 trial showed that the epcoritamab combination reduced the risk of disease progression or death by 51% in lymphoma patients.
AbbVie and Genmab reported successful topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating epcoritamab for the treatment of diffuse large B-cell lymphoma. Stock Titan reported that the trial demonstrated the epcoritamab combination reduced the risk of disease progression or death by 51% in the studied patient population.
The global study focused on newly diagnosed patients with an International Prognostic Index (IPI) score of 2 to 5. Regarding market performance, ABBV closed at $262.82 on October 2, 2026, having reached a session high of $264.06 and a low of $257.87 during that trading day.